ZLAB Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ZLAB from our risk checks.
Zai Lab Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$19.03 |
52 Week High | US$31.22 |
52 Week Low | US$13.48 |
Beta | 1.05 |
11 Month Change | 0.90% |
3 Month Change | 3.09% |
1 Year Change | -16.57% |
33 Year Change | -86.33% |
5 Year Change | -41.64% |
Change since IPO | 5.72% |
Recent News & Updates
Recent updates
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Shareholder Returns
ZLAB | US Biotechs | US Market | |
---|---|---|---|
7D | 12.0% | 0.7% | 0.1% |
1Y | -16.6% | 15.8% | 24.9% |
Return vs Industry: ZLAB underperformed the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: ZLAB underperformed the US Market which returned 25.9% over the past year.
Price Volatility
ZLAB volatility | |
---|---|
ZLAB Average Weekly Movement | 6.3% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ZLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: ZLAB's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
ZLAB fundamental statistics | |
---|---|
Market cap | US$1.77b |
Earnings (TTM) | -US$298.33m |
Revenue (TTM) | US$322.71m |
5.8x
P/S Ratio-6.3x
P/E RatioIs ZLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZLAB income statement (TTM) | |
---|---|
Revenue | US$322.71m |
Cost of Revenue | US$376.55m |
Gross Profit | -US$53.84m |
Other Expenses | US$244.49m |
Earnings | -US$298.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.04 |
Gross Margin | -16.68% |
Net Profit Margin | -92.44% |
Debt/Equity Ratio | 10.0% |
How did ZLAB perform over the long term?
See historical performance and comparison